STAT
STAT+: Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
Where should the safety bar be for studies investigating CAR-T therapies for autoimmune conditions?
Gene-editing news
These headlines leave this site
CRISPR Decoded reports no news of its own. Every headline below belongs to the publisher named beside it and opens on their website in a new tab, where their terms, paywalls and tracking apply. We will confirm before sending you.
STAT
STAT+: Pharmalittle: We’re reading about Beam suing over IP theft, a Trump rule on importing meds, and more
Gene-editing company Beam Therapeutics is alleging that one of its scientists stole intellectual property and used it to co-found a Chinese company
Beam Therapeutics
STAT
STAT+: Beam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual property
The gene-editing company Beam Therapeutics is alleging that one of its scientists stole intellectual property and used it to co-found a Chinese company that made a deal with VC…
Beam Therapeutics
Oct 27, 2026
Bonjour Genomics: A Video from ASHG
GEN editors Uduak Thomas and Julianna LeMieux, PhD, recap ASHG, highlighting key sessions, Ultima Genomics’ user group meeting, Illumina news, and insights from PacBio’s new CEO Mark Van…
Oct 26, 2026
Spatial Proteomics for Precision Oncology
In this GEN webinar, Bernd Bodenmiller, PhD (University of Zürich), illustrates this integrated approach through two recent examples. The post Spatial Proteomics for Precision Oncology…
Cancer
Oct 23, 2026
Bristol Myers reveals death in MS CAR-T trial, has answer for safety signal in lupus trial
A patient has died in a Bristol Myers Squibb study of autoimmune CAR-T, the same technology that was called into question this summer when both Bristol Myers and Novartis paused similar…
Oct 16, 2026
ADC Development from Concept to Clinic
This eBook brings insight on integrated end-to-end solutions for precision engineered therapeutics. The post ADC Development from Concept to Clinic appeared first on GEN - Genetic…
Oct 9, 2026
How COVID, Characterization, and Commerce Are Driving an RNA Revolution
COVID-19 accelerated efforts to develop faster, more efficient ways of manufacturing high-quality RNA sequences. The post How COVID, Characterization, and Commerce Are Driving an RNA…
Spatial Biology Moves Toward Translation
Spatial technologies preserve tissue context to guide therapeutic development and translate molecular insights into clinically actionable information. The post Spatial Biology Moves Toward…
Oct 7, 2026
Oct 6, 2026
Lock Down the Critical Factors in Oligo and Oligo-Conjugate Characterization with Stunner and Honeybun
This GEN webinar follows oligo quantification from method development through conjugate characterization. The post Lock Down the Critical Factors in Oligo and Oligo-Conjugate…
Inside All-ScaleFlow: Continuous End-to-End RNA-LNP Manufacturing
Dillico’s GMP-ready Continuous Manufacturing by Engineering, Not Hype The post Inside All-ScaleFlow: Continuous End-to-End RNA-LNP Manufacturing appeared first on GEN - Genetic Engineering…
Sep 29, 2026
Beam sues YolTech and Serapha Bio for allegedly stealing its gene editing tech
Beam Therapeutics, a Cambridge, MA-based company developing CRISPR base editing therapies, has sued two Chinese scientists and two biotech companies where they work for allegedly stealing…
Beam Therapeutics Base Editing
Sep 25, 2026
New CRISPR-Based Tool Enables Genome-Wide Mutagenesis of Bacteriophages
A CRISPR-based method for disrupting genes across bacteriophage genomes has been developed, creating a faster route to uncover gene functions and engineer phages for potential therapeutic…
Sep 22, 2026
Biomimetic Nanoparticles Trigger Light Responses in Blind Mouse Retinas
A biomimetic nanoparticle platform inspired by photosynthesis helped activate surviving retinal nerve cells in mice with advanced retinal degeneration. The post Biomimetic Nanoparticles…
Sep 21, 2026
Emerging Trends in Fluid Transfers and Freeze-Thaw Workflows
In this GEN webinar, our expert speakers will discuss the latest trends, challenges, and innovations shaping fluid transfer and freeze-thaw workflows. The post Emerging Trends in Fluid…
Sep 10, 2026
PD-L2 Blockade May Reduce Harmful Aging Cell Buildup
Blocking PD-L2 reduced senescent cell accumulation in aged mice and improved measures tied to metabolic function and physical strength. The post PD-L2 Blockade May Reduce Harmful Aging Cell…
Highly Multiplexed Droplet Digital PCR for Ultra-Sensitive NSCLC Biomarker Detection in Research Workflows
In this GEN webinar, two experts will discuss the growing role of ddPCR in clinical research and translational oncology. The post Highly Multiplexed Droplet Digital PCR for Ultra-Sensitive…
CancerData Integrity as the Foundation for AI
In this sponsored podcast, LabVantage’s Gary Stimson digs into what it takes to build a data foundation for trustworthy AI. The post Data Integrity as the Foundation for AI appeared first…
Smarter Cell Culture Starts with Better Media
Advances in media optimization, cell engineering, and AI are reshaping intensified bioprocessing for higher productivity, better quality, and greater manufacturing efficiency. The post…
Top 10 Contract Development and Manufacturing Organizations 2026
A majority of biopharmas are expected to increase their reliance on CDMOs in coming years despite rising costs for their services. The post Top 10 Contract Development and Manufacturing…
Sep 9, 2026
Increasing CHO Cell Productivity
Overexpressing the gene Pabpc1 in CHO cell cultures increases productivity by 30–50%, offering a broadly applicable strategy to engineer highly productive cell lines for antibody…
Sep 4, 2026
STAT+: We’re reading about a Bristol CAR-T trial pause, Pfizer offloading a shelved candidate, and more
The latest pharma news from the Pharmalot campus brought to you by the Pharmalittle newsletter
Sep 1, 2026
Arsenal Biosciences cuts ‘majority’ of staff in move to in vivo CAR-T
Roughly a year after shedding half of its workforce, Arsenal Biosciences is trimming its headcount again by letting go of “the majority” of its staffers as a result of a pivot into in vivo…
Aug 31, 2026
Single-Use Comes of Age—What’s Next?
Single-use systems (SUS) bioprocessing technology has become mainstream. But the more interesting question today is what the industry needs next, and how SUS will enable the future. The…
Aug 28, 2026
From Images to Data
This eBook introduces the latest trends in quantitative spatial biology and how IMC is accelerating their adoption and success. The post From Images to Data appeared first on GEN - Genetic…
Aug 26, 2026
Sharpening an essential tool for biotechnology
Scientists at the Department of Energy (DOE)'s Oak Ridge National Laboratory (ORNL) have shown that more than 93% of possible E. coli CRISPR-Cas9 guide RNAs—molecules that direct the…
CRISPR-Cas9
Aug 24, 2026
News on AstraZeneca, Cytokinetics, Novartis — what to look out for at ESC 2026
AstraZeneca, Ionis, Cytokinetics, Novartis and CRISPR Therapeutics, among others, will get a sense of the market potential of their heart drugs when data is presented this week at the…
CRISPR Therapeutics
Aug 20, 2026
Is Targeted Protein Degradation the “Break” Neurology Needs?
In this webinar, The post Is Targeted Protein Degradation the “Break” Neurology Needs? appeared first on GEN - Genetic Engineering and Biotechnology News .
Aug 17, 2026
The Microbiome Field Enters Its Next Chapter
New analytical tools and microbiome-based therapies are pushing the field beyond early hype toward clinical and scientific progress. The post The Microbiome Field Enters Its Next Chapter…
Rewriting Disease: Oligonucleotides Take Aim at the Untreatable
How synthetic DNA and RNA are becoming the discovery engines behind a new generation of precision therapies. The post Rewriting Disease: Oligonucleotides Take Aim at the Untreatable…
Aug 5, 2026
Gene-edited beagles may offer a future option for people with dog allergies
Scientists at a biotech company have used gene editing to create two hypoallergenic beagles that don't trigger allergies Matt Walker couldn’t pet a dog without sneezing – until he and other…
Not journalism: written in-house
CRISPR Decoded briefs
Short summaries produced with AI assistance from our own database records. They are not reported by anyone else, carry no byline, and are kept separate from the news above for exactly that reason.
How to read the evidence levels on this site
CRISPR Decoded organises its 92 pages across four evidence levels, and the distinction matters because it signals how much human data sits behind any claim. Laboratory research, covering 5 pages, describes work done entirely in cells or computer models. No human has received anything at this stage. Preclinical research, covering 12 pages, adds animal studies but still involves no human trials. Both levels indicate that a technology or disease application is at an exploratory stage, and according to CRISPR Decoded records, conditions such as Parkinson's disease sit at laboratory research while Duchenne muscular dystrophy remains preclinical. Clinical research is the largest category, with 59 pages. It covers every phase of human trials, from first-in-human Phase I studies through to Phase III registrational programmes. Being in clinical research means human data exists, but it does not mean a therapy is proven safe, effective or available. Approved treatment, covering 16 pages, is reserved for therapies that have cleared regulatory review. According to CRISPR Decoded records, only one gene editing therapy, Casgevy, holds that status, making the approved category the narrowest and most consequential distinction of all.
17h agoThe hardest unsolved problems
Approved gene editing treatments exist today for sickle cell disease and beta thalassemia, and the records of CRISPR Decoded point to a shared reason: both diseases involve blood stem cells that can be removed from a patient, edited outside the body, and returned. This ex vivo approach sidesteps one of the hardest problems in the field, namely delivering editing machinery reliably to cells inside a living person. Casgevy, a CRISPR-Cas9 therapy, reached approval on exactly this basis. Conditions that require editing inside the body face a steeper path. The liver is relatively accessible via lipid nanoparticles, which is why ATTR amyloidosis and hereditary angioedema have reached Phase III. Tissues such as muscle, the central nervous system and the lung are harder to reach, and Duchenne muscular dystrophy, Huntington's disease and cystic fibrosis remain preclinical in these records. A 2025 death in the MAGNITUDE liver-targeting trial also illustrated a further constraint: an irreversible in vivo edit cannot be withdrawn if something goes wrong, raising the safety threshold regulators apply.
17h agoWhat has changed most recently
According to CRISPR Decoded records, the most recent developments span 2023 to 2026 and range from a landmark approval to the first positive Phase 3 result for in vivo gene editing. In November 2023, the UK MHRA authorised Casgevy, a CRISPR-Cas9 therapy, for sickle cell disease and beta thalassemia, with FDA authorisation following in December 2023 and January 2024. This represents an approved treatment, the highest evidence level recorded. In 2025, results from PM359 in chronic granulomatous disease provided the first clinical evidence for prime editing, rated clinical research: prime-edited stem cells engrafted and restored immune function. That same year, a participant in the Phase 3 MAGNITUDE trial of nexiguran ziclumeran died following severe liver injury, prompting a voluntary pause and an FDA clinical hold. The hold on MAGNITUDE was later lifted. In 2026, Intellia reported positive Phase 3 results, clinical research evidence, for lonvoguran ziclumeran in hereditary angioedema, described in CRISPR Decoded records as the first successful registrational trial of in vivo gene editing, with a licence application signalled for later that year.
17h agoWhere gene editing actually stands today
As reflected in CRISPR Decoded records, one gene editing treatment has reached regulatory approval: Casgevy, a CRISPR-Cas9 therapy for sickle cell disease and beta thalassemia, authorised first by the UK MHRA in November 2023 and subsequently by the FDA. Two approved lentiviral gene-addition therapies, Lyfgenia and Zynteglo, address the same blood disorders but use a different mechanism and are not gene editing. Four gene editing programmes have reached Phase III. Nexiguran ziclumeran targets ATTR amyloidosis, lonvoguran ziclumeran targets hereditary angioedema and reported the first positive Phase III result for in vivo gene editing, risto-cel uses base editing for sickle cell disease, and BEAM-302 applies base editing to alpha-1 antitrypsin deficiency. Several earlier-stage trials cover cancer, familial hypercholesterolemia, chronic granulomatous disease and diabetes. A significant portion of the broader landscape remains preclinical or at discovery stage, including programmes for Duchenne muscular dystrophy, cystic fibrosis, hemophilia, Huntington's disease, Parkinson's disease and Alzheimer's disease, underlining how much of gene editing's potential has not yet been tested in humans.
17h agoWhere these headlines come from
Every publisher CRISPR Decoded collects from, with how many of their stories it currently holds.
| Publisher | Articles held | Most recent |
|---|---|---|
| GEN — Genetic Engineering News | 65 | Oct 27, 2026 |
| Endpoints News | 50 | Oct 27, 2026 |
| Nature Genetics | 30 | Oct 26, 2026 |
| STAT | 24 | Oct 27, 2026 |
| Phys.org — Molecular Biology | 20 | Oct 27, 2026 |
| Medical Xpress — Genetics | 15 | Oct 22, 2026 |
| Science Daily — Gene Therapy | 6 | Sep 7, 2025 |
| The Guardian — Genetics | 6 | Sep 21, 2026 |
| Science Daily — Genes | 5 | Oct 7, 2026 |
| Science Daily | 2 | Aug 17, 2026 |
| New Scientist | 2 | Sep 25, 2026 |
| FDA | 2 | Sep 17, 2026 |
| MIT Technology Review | 2 | Aug 14, 2026 |
Headlines, publisher names and links only. Articles remain the property of the publishers named. Dates are the publication dates reported by each feed, in UTC. Images, where shown, are served from the publisher and belong to them.